1 May 2019

Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker

LONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with its associates, "N+1 Singer") as nominated adviser and UK corporate broker to the Company with immediate effect.

For further information contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
 
Tel: +44 (0)20 3283 4200
info@veronapharma.com

 
N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Mia Gardner (Corporate Broking)
Tel: +44 (0)20 7496 3000
  
ICR, Inc. (US Media and Investor enquiries)
Darcie Robinson

Stephanie Carrington
Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 922 0891
verona@optimumcomms.com

Westwicke, an ICR Company (US Media and Investor enquiries)
Darcie Robinson
Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us